Adicet Bio (ACET) has announced that the FDA has granted Fast Track Designation to its therapeutic candidate, ADI-270, for treating patients with metastatic or advanced clear cell renal cell carcinoma who have previously received an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor. ADI-270 is an engineered, allogeneic "off-the-shelf" gamma delta CAR T cell therapy designed to target CD70-positive cancers.
Fast Track Designation is a mechanism aimed at accelerating the development and review process for drugs intended to treat severe conditions with unmet medical needs.
